Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder

Completed · Phase 2

Conditions studied: Bipolar Disorder

In brief

The purpose of this study is to examine how the drug tamoxifen affects the brain in patients with bipolar I disorder. Bipolar Disorder (BD) is a severe, chronic, and often life-threatening illness for which safe and effective treatments are necessary. The mood stabilizing effects of lithium and valproate have revolutionized the treatment of patients with BD. However, a significant percentage of patients do not respond fully to these drugs, and the biochemical basis for the antimanic and mood-stabilizing actions of lithium and valproate is unclear. Both drugs inhibit protein kinase C (PKC). There is a need to investigate the efficacy of a direct PKC inhibitor in the treatment of acute mania. Tamoxifen is currently the only relatively selective PKC inhibitor available for human use. Participants in this study will be screened with a physical, psychiatric, and eye examination and blood and urine tests. Eligible participants will be hospitalized at the Clinical Center for at least 4 weeks. They will be tapered off all psychiatric medication and kept drug free for 2 to 7 days. They will also be put on a low-monoamine, low-caffeine diet. Participants will be randomly assigned to receive either tamoxifen or placebo (an inactive pill) for 3 weeks. During this time, participants will have daily pulse and blood pressure measurements, several electrocardiograms (EKGs), and blood draws. Weight measurements will be taken at least twice during the study, and caffeine or dextromethorphan will be given at the beginning and end of the study to test how tamoxifen affects the way the body eliminates other medications. Participants will have a physical examination at the end of the study. At the end of this 4-week study, some participants may continue the study and will receive tamoxifen for an additional 3 weeks. At the conclusion of the study, participants' psychiatric status will be reassessed and long-term psychiatric treatment for their mood disorders will be arranged.

Key facts

Study ID

NCT00026585

Run by

National Institute of Mental Health (NIMH)

People needed

50

Starts

2001-11-09

Expected to finish

2007-11-02

Last updated by the study team

2017-07-02

Who can join

Age: 18 and older, up to 65. Sex: male. Healthy volunteers: not accepted.

You may not qualify if…

• Patients will be excluded from the study for any of the following reasons:
• Female patients who are either pregnant, nursing, or who are perimenopausal or postmenopausal.
• QTc of greater than 450 msec.
• Participation in a clinical trial of another investigational drug within 1 month (30 days) prior to study entry (Visit 1).
• Has received an antidepressant within 4 weeks prior to Visit 1 [8 weeks for fluoxetine].
• Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
• Presence of a coagulation disorder, history of deep venous thrombosis or pulmonary embolism.
• History of breast or uterine cancer, or abnormal uterine bleeding.
• Uncorrected hypothyroidism or hyperthyroidism.
• Presence of retinal pathology.
• One or more seizures without a clear and resolved etiology.
• Current leukopenia or thrombocytopenia.
• Clinical significant abnormal laboratory tests.
• Documented history of hypersensitivity or intolerance to TAM.
• DSM-IV substance abuse or dependence (except nicotine and caffeine) within the past 30 days.
• Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections prior to Visit 2.
• Treatment with a reversible monoamine oxidase inhibitor, guanethidine, or guanadrel within 1 week prior to Visit 2.
• Treatment with a nonreversible monoamine oxidase inhibitor within 2 weeks prior to Visit 2.
• Treatment with any other concomitant medication with primarily CNS activity, other than specified in Appendix B of Protocol 1 day prior to Visit 2.
• Treatment with clozapine within 4 weeks prior to Visit 2.
• Current diagnosis of schizophrenia or other psychotic disorder as defined in the DSM-IV.
• Judged clinically to be at serious suicidal risk.
• Concomitant treatment with a coumarin-type anticoagulant, phenobarbital, cyclophosphamide, or bromocriptine.

Where it is running

• Howard University Hospital — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.